Jun 30, 2026
17 MIN READ

When Did Ozempic Come Out for Weight Loss: A Comprehensive Exploration

Semaglutide gained FDA approval for chronic weight management in November 2021 under the brand name Wegovy, marking a major shift in obesity treatment. PlexusDx offers compounded semaglutide injection starting at $149/month, making this proven therapy accessible without insurance or membership fees.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 30, 2026
17 MIN READ

when did ozempic come out for weight loss: a comprehensive exploration — PlexusDx GLP-1 education

Last reviewed: June 30, 2026

Last updated: June 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide entered the weight loss market in 2021 when the FDA approved Wegovy, a higher-dose formulation of the diabetes medication Ozempic. This approval launched a new era in obesity care, backed by clinical trials showing 15% average body weight reduction. PlexusDx delivers compounded semaglutide from licensed 503A pharmacies across all 50 states, offering patients a direct path to this evidence-based therapy.

The FDA Timeline: When Semaglutide Won Approval for Weight Loss

Ozempic, made by Novo Nordisk, launched in the United States in 2017 for type 2 diabetes management at lower doses (0.5–1.0 mg weekly). Clinicians and patients soon noticed significant weight loss as a side effect, sparking interest in exploring semaglutide specifically for obesity treatment. The company began a dedicated development program, completing the STEP clinical trial series between 2019 and 2020.

The FDA granted approval to Wegovy (semaglutide for weight loss) on November 4, 2021, following the submission of STEP trial data. Wegovy uses doses up to 2.4 mg weekly—higher than Ozempic's diabetes dosing—and targets adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. This approval was groundbreaking because it represented the first GLP-1 receptor agonist designed and formally labeled for chronic weight management rather than diabetes as a side benefit.

Between 2021 and 2024, semaglutide-based weight loss therapy evolved from a specialty treatment to mainstream demand, creating widespread shortages and access barriers. Compounding pharmacies stepped in to serve patients unable to access or afford brand-name Wegovy, offering alternative pathways through licensed 503A facilities. PlexusDx emerged during this period to deliver personalized semaglutide therapy without insurance requirements or membership commitments.

How Semaglutide Works: The GLP-1 Mechanism Behind Weight Loss

Semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone your gut naturally releases when you eat. This hormone signals your brain to reduce hunger, slow stomach emptying, and increase feelings of fullness—creating a coordinated response that cuts calorie intake without willpower alone. The drug's half-life of approximately 7 days allows once-weekly dosing, making it practical for long-term use.

Clinical evidence from the STEP trials demonstrated that semaglutide produced an average 15% body weight loss over 68 weeks when combined with lifestyle changes, compared to 2.6% with placebo. Participants experienced reduced cravings, smaller portion sizes, and decreased food preoccupation—changes that persist as long as the medication is taken. These outcomes apply across diverse populations, though individual responses vary based on genetics, metabolism, and adherence.

Brand-Name Wegovy vs. Compounded Semaglutide: Access and Cost Differences

Wegovy typically costs $900–$1,500 monthly through traditional insurance or cash pay, with many plans requiring prior authorization or denying coverage altogether. Supply chain delays and manufacturing constraints have created persistent shortages, forcing patients onto waitlists or steering them toward alternatives. Compounded semaglutide from licensed 503A pharmacies offers the same active ingredient at significantly lower prices without insurance gatekeeping.

PlexusDx's compounded semaglutide injection starts at $149 per month across all 50 states, with no membership fee and HSA/FSA eligibility. Your dose may need to go up, but your price won't—this commitment ensures predictable, affordable access regardless of escalation through the treatment protocol. PlexusDx partners exclusively with licensed 503A compounding pharmacies that meet rigorous quality and sterility standards, differentiating this approach from unregulated online suppliers.

Beyond cost, compounded semaglutide offers faster access without prior authorization delays or insurance reviews. Patients can begin treatment within days of consultation, and dose adjustments happen seamlessly based on individual tolerability and response. This direct model appeals to those seeking autonomy over their weight loss journey without bureaucratic friction.

Personalized Semaglutide Therapy: Genetic Testing for Optimal Results

Not all patients respond equally to semaglutide, and genetic variation in GLP-1 signaling pathways explains some of this difference. PlexusDx's Precision Peptide Genetic Test analyzes 14 metabolic pathways and 150+ genetic insights, including variants in the GLP1R gene (rs6923761) and FTO gene (rs9939609) that influence medication response and weight loss capacity. This $99 add-on test, available after the first month of treatment, helps predict individual suitability and optimize dosing strategies.

The test examines key genetic markers: GIPR rs1800437 (glucose-dependent insulinotropic polypeptide receptor sensitivity), GLP1R rs6923761 (GLP-1 receptor function), FTO rs9939609 (metabolic predisposition), and MC4R rs17782313 (appetite regulation). Patients with favorable genetic profiles often achieve faster weight loss and better tolerance, while others may benefit from combination therapies or alternative dosing schedules. This precision approach transforms semaglutide from a one-size-fits-all medication into a personalized tool aligned with your biology.

What to Expect When Starting Semaglutide: Dosing, Timeline, and Results

Semaglutide treatment begins at a low dose (typically 0.25 mg weekly) and escalates gradually every 4 weeks to minimize side effects and allow your body to adapt. Most patients reach therapeutic doses (1.0–2.4 mg weekly) over 16–20 weeks. Weight loss typically begins in the first 2–4 weeks as appetite suppression kicks in, with cumulative reductions accelerating through months 3–6.

Common initial side effects include mild nausea, constipation, and decreased appetite for certain foods—most resolve within 1–2 weeks. Staying hydrated, eating smaller meals, and maintaining consistent dosing schedules reduce discomfort. Serious side effects are rare but include pancreatitis (sudden severe abdominal pain) and severe dehydration; these require immediate medical attention.

Long-term success depends on lifestyle integration: portion control, protein-rich meals, regular movement, and stress management amplify semaglutide's effect. Clinical data shows that weight loss plateaus if medication is discontinued, returning to baseline within 12 months. Patients viewing semaglutide as a long-term tool—not a temporary fix—achieve sustained results and metabolic health improvements including blood pressure reduction and improved insulin sensitivity.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide as effective as brand-name Wegovy?

Yes. Compounded semaglutide from licensed 503A pharmacies contains the same active ingredient and concentration as Wegovy, producing equivalent weight loss and metabolic benefits. PlexusDx sources from regulated facilities meeting strict sterility and potency standards, ensuring clinical effectiveness at a fraction of the cost.

When did doctors start using semaglutide off-label for weight loss before FDA approval?

Clinicians began prescribing Ozempic off-label for weight management around 2019–2020 after noticing significant weight loss in diabetic patients. This informal use preceded Wegovy's formal FDA approval in November 2021, though prescribing off-label carried no official weight-loss indication and often faced insurance denials.

How much does PlexusDx compounded semaglutide cost, and what's included?

PlexusDx compounded semaglutide injection starts at $149 per month with no insurance required, membership fees, or flat per-compound pricing increases. Your dose may need to go up, your price won't. HSA and FSA accounts are eligible, and treatment is available across all 50 states with no authorization delays.

What happens if I have a genetic predisposition that makes semaglutide less effective?

PlexusDx's Precision Peptide Genetic Test ($99 add-on) identifies genetic variants affecting GLP-1 receptor sensitivity and metabolic response. If your results show lower predicted response, PlexusDx can recommend combination therapies, adjusted dosing strategies, or alternative compounds like tirzepatide to optimize your weight loss outcomes.

Is semaglutide safe for long-term use?

Semaglutide has demonstrated safety in clinical trials extending beyond two years, with most side effects being mild and self-resolving. Long-term monitoring with your provider is recommended to track metabolic markers and ensure sustained benefit. Serious complications like pancreatitis are rare but require immediate medical evaluation if abdominal pain occurs.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves